Swissmedic approves IFINWIL® (eflornithine) for children diagnosed with high-risk neuroblastoma (...

Swissmedic approves IFINWIL® (eflornithine) for children diagnosed with high-risk neuroblastoma (HRNB)  PR Newswire

Swissmedic approves Novartis’ malaria medicine for babies - Pharmaceutical Technology

Swissmedic approves Novartis’ malaria medicine for babies  Pharmaceutical Technology

Euro Roundup: Swissmedic pilots fast-track procedure to accelerate clinical trial authorizations ...

Euro Roundup: Swissmedic pilots fast-track procedure to accelerate clinical trial authorizations  Regulatory Affairs Professionals Society | RAPS

Swissmedic approves first malaria treatment for infants - drugdiscoverytrends.com

Swissmedic approves first malaria treatment for infants  drugdiscoverytrends.com

Swissmedic Launches Pilot To Expedite Clinical Trial Applications - insights.citeline.com

Swissmedic Launches Pilot To Expedite Clinical Trial Applications  insights.citeline.com

Urgent amendment to the Swiss Pharmacopoeia - Swissmedic

Urgent amendment to the Swiss Pharmacopoeia  Swissmedic

Swissmedic reinforces Switzerland’s role in global regulatory collaboration and advanced therapeu...

Swissmedic reinforces Switzerland’s role in global regulatory collaboration and advanced therapeutics  Greater Geneva Bern area

Euro Roundup: Swissmedic mandates nitrosamine risk assessments in some applications - Regulatory ...

Euro Roundup: Swissmedic mandates nitrosamine risk assessments in some applications  Regulatory Affairs Professionals Society | RAPS

Swissmedic Appoints Trivigno As New Agency Head From 2026 - insights.citeline.com

Swissmedic Appoints Trivigno As New Agency Head From 2026  insights.citeline.com

Swissmedic Accepts Marketing Authorization Application for Piflufolastat (18F) for Prostate Cance...

Swissmedic Accepts Marketing Authorization Application for Piflufolastat (18F) for Prostate Cancer  OncLive

Collaborative training of regulators as an approach for strengthening regulatory systems in LMICs...

Collaborative training of regulators as an approach for strengthening regulatory systems in LMICs: experiences of the WHO and Swissmedic  Frontiers

Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory...

Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective  ASCO Publications

Swissmedic reorg adds new focus on medical device market surveillance - AgencyIQ by POLITICO

Swissmedic reorg adds new focus on medical device market surveillance  AgencyIQ by POLITICO

Swissmedic issues warning about the illegal medicinal product "Lemon Bottle" lipolysis solution -...

Swissmedic issues warning about the illegal medicinal product "Lemon Bottle" lipolysis solution  Swissmedic

Swissmedic approves Orchard’s gene therapy for early-onset MLD - Pharmaceutical Technology

Swissmedic approves Orchard’s gene therapy for early-onset MLD  Pharmaceutical Technology

Euro Roundup: Swissmedic updates responsible person document, asks for immediate action - Regulat...

Euro Roundup: Swissmedic updates responsible person document, asks for immediate action  Regulatory Affairs Professionals Society | RAPS

Euro Roundup: Swissmedic revises four medicines authorization guidances - Regulatory Affairs Prof...

Euro Roundup: Swissmedic revises four medicines authorization guidances  Regulatory Affairs Professionals Society | RAPS

Swissmedic updates guidances on API, fast-track pathway, and more - Regulatory Affairs Profession...

Swissmedic updates guidances on API, fast-track pathway, and more  Regulatory Affairs Professionals Society | RAPS

Swissmedic survey finds drug approval timelines slower than EMA, FDA - Regulatory Affairs Profess...

Swissmedic survey finds drug approval timelines slower than EMA, FDA  Regulatory Affairs Professionals Society | RAPS

Swissmedic updates adverse event reporting requirements for 2024 - Regulatory Affairs Professiona...

Swissmedic updates adverse event reporting requirements for 2024  Regulatory Affairs Professionals Society | RAPS

Swissmedic updates guidance on temporary medicine authorization to harmonize deadlines - Regulato...

Swissmedic updates guidance on temporary medicine authorization to harmonize deadlines  Regulatory Affairs Professionals Society | RAPS

Study: FDA more likely to approve drugs for broader populations than EMA, Swissmedic - Regulatory...

Study: FDA more likely to approve drugs for broader populations than EMA, Swissmedic  Regulatory Affairs Professionals Society | RAPS

Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility ...

Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland  Biogen

Counterfeit Ozempic diabetes medication in circulation - Swissmedic

Counterfeit Ozempic diabetes medication in circulation  Swissmedic

Pfizer applies to Swissmedic for authorisation of another COVID-19 vaccine - Reuters

Pfizer applies to Swissmedic for authorisation of another COVID-19 vaccine  Reuters

Kamada’s Glassia receives marketing approval from Swissmedic - Pharmaceutical Technology

Kamada’s Glassia receives marketing approval from Swissmedic  Pharmaceutical Technology

CARBOGEN AMCIS passes Swissmedic inspection - European Pharmaceutical Manufacturer

CARBOGEN AMCIS passes Swissmedic inspection  European Pharmaceutical Manufacturer

Hemophilia B gene therapy Hemgenix approved in Switzerland - Hemophilia News Today

Hemophilia B gene therapy Hemgenix approved in Switzerland  Hemophilia News Today

Swissmedic moves more slowly in reviewing medicines - The Pharma Letter

Swissmedic moves more slowly in reviewing medicines  The Pharma Letter

Euro Roundup: Swissmedic posts Q&A on filing applications, documents for clinical trials - Regula...

Euro Roundup: Swissmedic posts Q&A on filing applications, documents for clinical trials  Regulatory Affairs Professionals Society | RAPS

No indication of risk due to COVID-19 booster shot bubbles -Swissmedic - Reuters

No indication of risk due to COVID-19 booster shot bubbles -Swissmedic  Reuters

First malaria treatment for newborn babies approved for use - The Washington Post

First malaria treatment for newborn babies approved for use  The Washington Post

Swiss drug review times trail FDA and EMA, increased due to COVID - Regulatory Affairs Profession...

Swiss drug review times trail FDA and EMA, increased due to COVID  Regulatory Affairs Professionals Society | RAPS

Novartis gains Swissmedic approval for malaria treatment for infants - World Pharmaceutical Front...

Novartis gains Swissmedic approval for malaria treatment for infants  World Pharmaceutical Frontiers

Landmark listing of first three countries as WHO-Listed regulatory Authorities - World Health Org...

Landmark listing of first three countries as WHO-Listed regulatory Authorities  World Health Organization (WHO)

Swissmedic Approves Hemgenix Gene Therapy for Hemophilia B - NAVLIN DAILY

Swissmedic Approves Hemgenix Gene Therapy for Hemophilia B  NAVLIN DAILY

Swissmedic and the UK Veterinary Medicines Directorate agree collaboration on veterinary medicina...

Swissmedic and the UK Veterinary Medicines Directorate agree collaboration on veterinary medicinal products  Swissmedic

Novartis given green light for infant anti-malaria drug - SWI swissinfo.ch

Novartis given green light for infant anti-malaria drug  SWI swissinfo.ch

Operation Pangea XVI: International campaign against falsified and illegally imported medicinal p...

Operation Pangea XVI: International campaign against falsified and illegally imported medicinal products  Swissmedic

Journey of blood - Visible - Swissmedic

Journey of blood - Visible  Swissmedic

Side effects of COVID-19 vaccines in Switzerland – update - Swissmedic

Side effects of COVID-19 vaccines in Switzerland – update  Swissmedic

CHUV introduces Switzerland's first gut-balancing medication - Greater Geneva Bern area

CHUV introduces Switzerland's first gut-balancing medication  Greater Geneva Bern area

Swissmedic agrees closer collaboration in therapeutic products field with Dutch partner authority...

Swissmedic agrees closer collaboration in therapeutic products field with Dutch partner authority  Swissmedic

VMD and Swissmedic agree collaboration on veterinary medicinal products - GOV.UK

VMD and Swissmedic agree collaboration on veterinary medicinal products  GOV.UK

“Revolving doors” with the pharmaceutical industry: a major source of influence on Swiss regulato...

“Revolving doors” with the pharmaceutical industry: a major source of influence on Swiss regulatory bodies?  Public Eye

Cannabis for medical purposes - Visible - Swissmedic

Cannabis for medical purposes - Visible  Swissmedic

Insights into complementary and herbal medicines - Swissmedic

Insights into complementary and herbal medicines  Swissmedic

Meet René: The IDF’s First Ever Swiss-Bedouin Medic - idf.il

Meet René: The IDF’s First Ever Swiss-Bedouin Medic  idf.il

Interview with Swissmedic Agency Council Chair Lukas Bruhin - Swissmedic

Interview with Swissmedic Agency Council Chair Lukas Bruhin  Swissmedic

Warning regarding Esillaa slimmers’ tea - Swissmedic

Warning regarding Esillaa slimmers’ tea  Swissmedic

“Out-of-stock requests are processed promptly when supply problems arise.” - Swissmedic

“Out-of-stock requests are processed promptly when supply problems arise.”  Swissmedic

Swissmedic vaccine videos – part 4 - Swissmedic

Swissmedic vaccine videos – part 4  Swissmedic

Falsified Ozempic diabetes medication in circulation - Swissmedic

Falsified Ozempic diabetes medication in circulation  Swissmedic

What does the name Swissmedic mean to you? - Swissmedic

What does the name Swissmedic mean to you?  Swissmedic

Side effects of COVID-19 vaccines in Switzerland – update - Swissmedic

Side effects of COVID-19 vaccines in Switzerland – update  Swissmedic

Swissmedic approves Kapruvia with additional regulatory decisions expected in H2 2022 - Indian Ph...

Swissmedic approves Kapruvia with additional regulatory decisions expected in H2 2022  Indian Pharma Post

Swissmedic approves Daiichi Sankyo's Lixiana - European Pharmaceutical Review

Swissmedic approves Daiichi Sankyo's Lixiana  European Pharmaceutical Review

Swiss regulator and media clash over weight-loss drugs - SWI swissinfo.ch

Swiss regulator and media clash over weight-loss drugs  SWI swissinfo.ch

'Sitting ducks': Volunteer describes rescue at besieged Kenyan hotel - Yahoo News Singapore

'Sitting ducks': Volunteer describes rescue at besieged Kenyan hotel  Yahoo News Singapore

Interview with Raimund Bruhin, Executive Director of Swissmedic - Swissmedic

Interview with Raimund Bruhin, Executive Director of Swissmedic  Swissmedic

Focus on safety - Visible - Swissmedic

Focus on safety - Visible  Swissmedic

Incomplete data stalls Swiss authorisation of Covid-19 vaccines - SWI swissinfo.ch

Incomplete data stalls Swiss authorisation of Covid-19 vaccines  SWI swissinfo.ch

The pharmacopoeia - Visible - Swissmedic

The pharmacopoeia - Visible  Swissmedic

MHRA and Swissmedic pledge greater collaboration - PMLiVE

MHRA and Swissmedic pledge greater collaboration  PMLiVE

Swissmedic authorises new drug for respiratory disease - SWI swissinfo.ch

Swissmedic authorises new drug for respiratory disease  SWI swissinfo.ch

Improving international collaboration – MHRA and Swissmedic sign MoU - GOV.UK

Improving international collaboration – MHRA and Swissmedic sign MoU  GOV.UK

Illegally imported medicinal products: underestimated risks! - Swissmedic

Illegally imported medicinal products: underestimated risks!  Swissmedic

Market surveillance - Visible - Swissmedic

Market surveillance - Visible  Swissmedic

Covid: booster doses of Pfizer vaccine authorised for everyone 16 and over in Switzerland - lenew...

Covid: booster doses of Pfizer vaccine authorised for everyone 16 and over in Switzerland  lenews.ch

Personalisierter Hirnstimulator bei Swissmedic registriert - Medinside

Personalisierter Hirnstimulator bei Swissmedic registriert  Medinside

Swissmedic stoppt Auslieferung von Novartis-Grippeimpfstoff - Neue Zürcher Zeitung

Swissmedic stoppt Auslieferung von Novartis-Grippeimpfstoff  Neue Zürcher Zeitung